Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis

Bak, Maarten; Fransen, Annemarie; Janssen, Jouke; van Os, Jim; Drukker, Marjan

doi:10.1371/journal.pone.0094112

Cited by 490Schizophrenia research and treatmentPharmacology and Obesity TreatmentEating Disorders and Behaviors

Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis

Open access

Bak, Maarten, Fransen, Annemarie, Janssen, Jouke, van Os, Jim, Drukker, Marjan·2014·PLoS ONE

DOI 10.1371/journal.pone.0094112PMC PMC3998960

Open this paper in CoChat — free account Open PDF

Abstract

INTRODUCTION: Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses generally are restricted to second generation antipsychotics (SGA) and do not stratify for duration of AP use. It is hypothesised that patients gain more weight if duration of AP use is longer. METHOD: A meta-analysis was conducted of clinical trials of AP that reported weight change. Outcome measures were body weight change, change in BMI and clinically relevant weight change (7% weight gain or loss). Duration of AP-use was stratified as follows: ≤6 weeks, 6-16 weeks, 16-38 weeks and >38 weeks. Forest plots stratified by AP as well as by duration of use were generated and results were summarised in figures. RESULTS: 307 articles met inclusion criteria. The majority were AP switch studies. Almost all AP showed a degree of weight gain after prolonged use, except for amisulpride, aripiprazole and ziprasidone, for which prolonged exposure resulted in negligible weight change. The level of weight gain per AP varied from discrete to severe. Contrary to expectations, switch of AP did not result in weight loss for amisulpride, aripiprazole or ziprasidone. In AP-naive patients, weight gain was much more pronounced for all AP. CONCLUSION: Given prolonged exposure, virtually all AP are associated with weight gain. The rational of switching AP to achieve weight reduction may be overrated. In AP-naive patients, weight gain is more pronounced.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0094112

Cites

364 of 364 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Lower BMI has been associated with higher risk of weight gain due to antipsychotics in meta-analyses and pooled analyses of brexpiprazole clinical studies.
“lower BMI has been associated with higher risk of weight gain due to antipsychotics in meta-analyses20 and pooled analyses of brexpiprazole clinical studies.21”
From Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy (2019) · cites this paper as [20]
Medication with antipsychotic drugs can be considered partly modifiable, as reducing doses or switching prescriptions only leads to moderate improvement of metabolic risk factors.
“Of these risk factors, medication with antipsychotic drugs can be considered partly modifiable, as reducing doses or switching prescriptions only leads to moderate improvement of metabolic risk factors 10,11 .”
From The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity (2016) · cites this paper as [10]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,706 · see citing works
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623 · see citing works
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · see citing works
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 6× · see citing works
“In addition, Allison [19] suggested to study clinically significant weight gain and weight loss and provided a definition.”
BackgroundMethodResultInfluential
A Systematic Review of Mortality in Schizophrenia: Is the Differential Mortality Gap Worsening Over Time?
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065 · cited 1× · see citing works
“Compared to the general population, the risk of developing cardiovascular illness is doubled and more than five times higher for endocrine disease [12,14].”
Background
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354 · see citing works
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206 · see citing works
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · cited 1× · see citing works
“Indeed some reviews address this issue although restricted to only schizophrenia and bipolar disorder [27,61].”
Background
Excess Mortality in Bipolar and Unipolar Disorder in Sweden
Ösby, U., Brandt, L., Correia, N., Ekbom, A., & Sparén, P. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.9.844 · Cited by 1,120 · cited 1× · see citing works
“6 in women [15].”
Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis
Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & Binder, M. D. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,087 · cited 1× · see citing works
“Within the group of SMI, the risk for weight gain is more enhanced for schizophrenia than for bipolar disorder [55,56].”
Background
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
McEvoy, J. M., Lieberman, J. A., Stroup, T. S., Thomas, S., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.4.600 · Cited by 1,019 · see citing works
A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk—a review of the literature
Huxley, R., Mendis, S., Zheleznyakov, E., Reddy, S., & Chan, J. C. N. (2009) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2009.68 · Cited by 772 · cited 1× · see citing works
“Overweight and particularly obesity predicts cardiovascular risk, metabolic syndrome (MS) and diabetes mellitus type 2 (DM-II) [1–5] as well as an increased risk for cancer [6,7].”
Background
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study
Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D., & GOFF, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.975 · Cited by 699 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Metabolic syndrome in people with schizophrenia: a review
DE HERT, M., SCHREURS, V., VANCAMPFORT, D., & VAN WINKEL, R. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00199.x · Cited by 634 · cited 1× · see citing works
“Within the group of SMI, the risk for weight gain is more enhanced for schizophrenia than for bipolar disorder [55,56].”
Background
Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder
Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., ZIMBROFF, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder
Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M. W., Stock, E. G., Stringfellow, J., Ingenito, G. G., & Marder, S. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.681 · Cited by 592 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression: A Double-blind, Placebo-controlled Study (The BOLDER II Study)
Thase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559 · see citing works
Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
McGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., A. Hawkins, K., E. Hoffman, R., Preda, A., Epstein, I., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.5.790 · Cited by 556 · see citing works
Efficacy of Olanzapine in Acute Bipolar Mania A Double-blind, Placebo-Controlled Study
Tohen, M. F. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.9.841 · Cited by 539 · see citing works
Novel antipsychotics: comparison of weight gain liabilities.
Wirshing, D. A., Wirshing, W. C., Kysar, L., Berisford, M. A., Goldstein, D., Pashdag, J., Mintz, J., & Marder, S. R. (1999) · PubMed · Cited by 523 · see citing works
A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar Mania
Keck, P. E., Marcus, R. N., Tourkodimitris, S., Ali, M. W., Liebeskind, A., Saha, A. R., Ingenito, G. G., & Aripiprazole Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1651 · Cited by 501 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials
Marder, S. R., McQuade, R. D., Stock, E. G., Kaplita, S., Marcus, R. N., Safferman, A. Z., Saha, A. R., Ali, M. W., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467 · see citing works
Depression and Risk of Mortality in People with Diabetes Mellitus: A Systematic Review and Meta-Analysis
van Dooren, F. E. P., Nefs, G., Schram, M. T., Verhey, F. R. J., Denollet, J., & Pouwer, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057058 · Cited by 441 · see citing works
Antipsychotic medications: metabolic and cardiovascular risk.
Newcomer, J. W. (2007) · PubMed · Cited by 417 · see citing works
Obesity among those with mental disorders: a National Institute of Mental Health meeting report.
Allison, D., Newcomer, J., Dunn, A., Blumenthal, J., Fabricatore, A., Daumit, G., Cope, M., Riley, W., Vreeland, B., Hibbeln, J., et al. (2009) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2008.11.020 · Cited by 411 · cited 1× · see citing works
“Indeed some reviews address this issue although restricted to only schizophrenia and bipolar disorder [27,61].”
Background
Novel Antipsychotics
Wirshing, D. A., Wirshing, W. C., Kysar, L., Berisford, M. A., Goldstein, D., Pashdag, J., Mintz, J., & Marder, S. R. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0602 · Cited by 392 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup, T. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.4.611 · Cited by 354 · see citing works
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Schooler, N. R., Rabinowitz, J., Davidson, M., Emsley, R. A., Harvey, P. D., Kopala, L. C., McGorry, P. D., Hove, I. V., Eerdekens, M., Swyzen, W., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.947 · Cited by 348 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Randomized Double-Blind Study of Risperidone and Olanzapine in the Treatment of Schizophrenia or Schizoaffective Disorder
Conley, R. R., & Mahmoud, R. A. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.5.765 · Cited by 336 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Comorbid Somatic Illnesses in Patients With Severe Mental Disorders: Clinical, Policy, and Research Challenges
Fleishhacker, W. W., Cetkovich-Bakmas, M., De Hert, M., Hennekens, C. H., Lambert, M., Leucht, S., Maj, M., McIntyre, R. S., Naber, D., Newcomer, J. W., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0401 · Cited by 328 · cited 2× · see citing works
“In general, it is concluded that AP add to the increased mortality risk of people with SMI either through direct cardio toxic effects or by impacting on weight gain [8,18].”
Background
Randomized, Placebo-Controlled Trial of Olanzapine as Maintenance Therapy in Patients With Bipolar I Disorder Responding to Acute Treatment With Olanzapine
Tohen, M., Calabrese, J. R., Sachs, G. S., Banov, M. D., Detke, H. C., Risser, R., Baker, R. W., Chou, J. C.-Y., & Bowden, C. L. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.247 · Cited by 317 · see citing works
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001) · PubMed · Cited by 317 · see citing works
Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials
Álvarez‐Jiménez, M., Hetrick, S. E., González‐Blanch, C., Gleeson, J., & McGorry, P. D. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.042853 · Cited by 315 · cited 1× · see citing works
“Psychiatrists should keep in mind that switching antipsychotics requires monitoring and evaluation [51] and may benefit from concurrent non-pharmacological interventions [58,59].”
Background
The metabolic effects of antipsychotic medications
Newcomer, J. W., & Haupt, D. W. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100803 · Cited by 315 · cited 2× · see citing works
“Overweight and particularly obesity predicts cardiovascular risk, metabolic syndrome (MS) and diabetes mellitus type 2 (DM-II) [1–5] as well as an increased risk for cancer [6,7].”
Background
Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic Schizophrenia
Pigott, T. A., Carson, W. H., Saha, A. R., Torbeyns, A. F., Stock, E. G., Ingenito, G. G., & Aripiprazole Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0910 · Cited by 309 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
Kasper, S. F., Lerman, M. N., McQuade, R. D., Saha, A. R., Carson, W. H., Ali, M. W., Archibald, D., Ingenito, G. G., Marcus, R. N., & Pigott, T. A. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003651 · Cited by 309 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Thomas, S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., DAVIS, C. E., Severe, J. B., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.611 · Cited by 306 · see citing works
Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial☆
Kane, J. M., Cañas, F., Kramer, M. L., Ford, L., Gassmann-Mayer, C., Lim, P., & Eerdekens, M. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.012 · Cited by 296 · see citing works
Factors Influencing Acute Weight Change in Patients With Schizophrenia Treated With Olanzapine, Haloperidol, or Risperidone
Basson, B. R., Kinon, B. J., Taylor, C. C., Szymanski, K. A., Gilmore, J. A., & Tollefson, G. D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0404 · Cited by 279 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq042 · Cited by 272 · cited 1× · see citing works
“A direct comparison between AP to calculate differences between the various AP was only presented by Rummel-Kluge, performing a head-to-head comparison [25] Leucht and colleagues [35] also showed that (i) all AP are associated with at least some weight gain compared with placebo and (ii) that olanzapine and clozapine…”
Result
Long-Term Olanzapine Treatment
Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0204 · Cited by 269 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders
Álvarez‐Jiménez, M., González‐Blanch, C., Crespo‐Facorro, B., Hetrick, S. E., Rodríguez-Sánchez, J. M., Pérez‐Iglesias, R., & Vázquez‐Barquero, J. L. (2008) · CNS Drugs · doi:10.2165/00023210-200822070-00002 · Cited by 266 · cited 3× · see citing works
“Another problem is that outcome of studies and meta-analyses are contaminated by two factors: (i) mix of study duration (short and long term studies) whereas effects on weight are delayed and (ii) no distinction is made between first episode of drug naive patients and chronic patients [20].”
BackgroundMethodResult
Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities
McIntyre, R. S., McCann, S., & Kennedy, S. H. (2001) · The Canadian Journal of Psychiatry · doi:10.1177/070674370104600308 · Cited by 261 · cited 2× · see citing works
“Subsequent metaanalyses confirmed the finding that most AP contributes to weight gain [20–26].”
Background
Aripiprazole Monotherapy in Nonpsychotic Bipolar I Depression: Results of 2 Randomized, Placebo-Controlled Studies
Thase, M. E., Jonas, A., Khan, A., Bowden, C. L., Wu, X., McQuade, R. D., Carson, W. H., Marcus, R. N., & Owen, R. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181618eb4 · Cited by 251 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine Treatment of Female Borderline Personality Disorder Patients
Zanarini, M. C., & Frankenburg, F. R. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1103 · Cited by 251 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Long-Term Efficacy and Safety of Iloperidone
Kane, J. M., Lauriello, J., LASKA, E. M., Marino, M. E. D., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318169cca7 · Cited by 250 · cited 1× · see citing works
“7 (, 6 wk, n = 1239) [45], levomepromazine 4.”
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study
Davidson, M., Emsley, R. A., Kramer, M. L., Ford, L., Pan, G., Lim, P., & Eerdekens, M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.003 · Cited by 249 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review
Binder, M. D., Schreurs, V., Sweers, K., Eyck, D. V., Hanssens, L., Šinko, S., Wampers, M., Scheen, A. J., Peuskens, J., & van Winkel, R. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.028 · Cited by 247 · see citing works
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study
Sachs, G. S., Sanchez, R., Marcus, R. N., Stock, E. G., McQuade, R. D., Carson, W. H., Abou-Gharbia, N., Impellizzeri, C., Kaplita, S., Rollin, L., et al. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106059693 · Cited by 245 · see citing works
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade, R. D., Stock, E. G., Marcus, R. N., Jody, D. N., Abou-Gharbia, N., Vanveggel, S., Archibald, D., & Carson, W. H. (2004) · PubMed · Cited by 244 · see citing works
Weight Gain Associated With Increased Food Intake and Low Habitual Activity Levels in Male Adolescent Schizophrenic Inpatients Treated With Olanzapine
Gothelf, D., Falk, B., Singer, P., Kairi, M., Phillip, M., Zigel, L., Poraz, I., Frishman, S., Constantini, N., Zalsman, G., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1055 · Cited by 242 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo
Keck, P. E., & Calabrese, J. R. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1003 · Cited by 238 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine Increases Weight and Serum Triglyceride Levels
Osser, D. N., Najarian, D. M., & Dufresne, R. L. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1109 · Cited by 231 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Waist circumference and waist/hip ratio in relation to all-cause mortality, cancer and sleep apnea
Seidell, J. C. (2009) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2009.71 · Cited by 231 · see citing works
Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study
Marder, S. R., Kramer, M. L., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M., & Lowy, A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.017 · Cited by 229 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania
Tohen, M. F., Goldberg, J. F., Arrillaga, A. M. G.-P., Azorin, J. M., Vieta, E., Hardy-Baylé, M. C., Lawson, W. B., Emsley, R. A., Zhang, F., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1218 · Cited by 229 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Risperidone Versus Pimozide in Tourette's Disorder
Bruggeman, R., van der Linden, C., Buitelaar, J. K., Gericke, G. S., Hawkridge, S. M., & Temlett, J. A. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0111 · Cited by 224 · cited 1× · see citing works
“9 (6– 16 wk, n = 24) [48] and zuclopentixol 0.”
Influence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224 · cited 7× · see citing works
“Long term use of antipsychotics (AP) is associated with increased mortality risk in people with SMI [16,17].”
BackgroundInfluential
Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With Schizophrenia
Kramer, M. L., Simpson, G. M., Mačiulis, V., Kushner, S. F., Vijapurkar, U., Lim, P., & Eerdekens, M. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802dda4a · Cited by 224 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder
Soler, J., Pascual, J. C., Campins, J., Barrachina, J., Puigdemont, D., Alvarez, E., & Pérez, V. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1221 · Cited by 224 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia
Yang, J.-W., Bahk, W., Cho, H.-S., Jeon, Y., Jon, D., Jung, H., Kim, C., Kim, H., Kim, Y., Kim, Y. H., et al. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181dcda50 · Cited by 220 · cited 1× · see citing works
“48 (6–16 wk, n = 92) [43], fluphenazine 22.”
Serious Cardiovascular Events and Mortality Among Patients with Schizophrenia
Enger, C. L., Weatherby, L. B., Reynolds, R. F., Glasser, D. B., & Walker, A. M. (2003) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000105996.62105.07 · Cited by 215 · cited 1× · see citing works
“Compared to the general population, the risk of developing cardiovascular illness is doubled and more than five times higher for endocrine disease [12,14].”
Background
Metabolic issues and cardiovascular disease in patients with psychiatric disorders
Casey, D. E. (2005) · The American Journal of Medicine Supplements · doi:10.1016/j.amjmed.2005.01.046 · Cited by 210 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
Zipursky, R. B., Gu, H., Green, A. I., Perkins, D. O., Tohen, M. F., McEvoy, J. P., Strakowski, S. M., Sharma, T., Kahn, R. S., Gur, R. E., et al. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.6.537 · Cited by 206 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study.
Hert, M. A. F. D., van Winkel, R., Eyck, D. V., Hanssens, L. S., Wampers, M., Scheen, A. J., & Peuskens, J. (2006) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-2-14 · Cited by 205 · see citing works
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine
Tollefson, G. D., Birkett, M. A., Kiesler, G. M., & Wood, A. J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01026-x · Cited by 202 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder
Quiroz, J. A., Yatham, L. N., Palumbo, J. M., Karcher, K., Kushner, S., & Kusumakar, V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.015 · Cited by 200 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease
Breier, A. F., Sutton, V. K., Feldman, P. D., Kadam, D. L., Ferchland, I., Wright, P., & Friedman, J. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01392-6 · Cited by 198 · cited 1× · see citing works
“One paper was treated as two separate studies, as it presented two separate data sets in a single paper [37].”
Method
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease
Deyn, P. P. D., Carrasco, M. M., Deberdt, W. G., Jeandel, C., Hay, D. P., Feldman, P. D., Young, C. A., Lehman, D. L., & Breier, A. F. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1032 · Cited by 198 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Obesity among individuals with serious mental illness
Dickerson, F., Brown, C. H., Kreyenbuhl, J. A., Fang, L., Goldberg, R. W., Wohlheiter, K. A., & Dixon, L. B. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00637.x · Cited by 198 · cited 1× · see citing works
“Patients with SMI have an increased risk for metabolic problems like obesity [9,53,54].”
Background
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
Chue, P. S., Eerdekens, M., Augustyns, I., Lachaux, B., Molčan, P., Eriksson, L., Pretorius, H., & David, A. S. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.07.003 · Cited by 197 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia
Kane, J. M., Detke, H. C., Naber, D., Sethuraman, G., Lin, D., Bergstrom, R. F., & McDonnell, D. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.07081221 · Cited by 196 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)
Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Nussbaum, A. M., Lieberman, J. A., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111609 · Cited by 194 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol
Smulevich, A. B., Khanna, S., Eerdekens, M., Karcher, K., Kramer, M., & Grossman, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.06.003 · Cited by 192 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Lurasidone in the Treatment of Acute Schizophrenia
Nakamura, M., Ogasa, M., Guarino, J. J., Phillips, D., Severs, J. M., Cucchiaro, J. B., & Loebel, A. D. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04905 · Cited by 191 · see citing works
Weight effects associated with antipsychotics: A comprehensive database analysis
Parsons, B., Allison, D. B., Loebel, A. D., Williams, K., Giller, E. L., Romano, S. J., & SIU, C. O. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.025 · Cited by 191 · cited 5× · see citing works
“In firstepisode schizophrenia patients, weight gain was more prominent compared to chronic patients [24].”
BackgroundMethodResultInfluential
A 3‐week, randomized, placebo‐controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states
McIntyre, R. S., Cohen, M., Zhao, J., Alphs, L. D., Macek, T. A., & Panagides, J. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00748.x · Cited by 189 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder
van Winkel, R., Binder, M. D., Eyck, D. V., Hanssens, L., Wampers, M., Scheen, A. J., & Peuskens, J. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00520.x · Cited by 187 · see citing works
Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association
Czobor, P., Volavka, J., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00003 · Cited by 185 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Double-Blind Comparative Study of Clozapine and Risperidone in the Management of Severe Chronic Schizophrenia
Azorin, J., Spiegel, R., Remington, G. J., Vanelle, J. M., Péré, J.-J., Giguere, M., & Bourdeix, I. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1305 · Cited by 179 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients With Schizophrenia
Meltzer, H. Y., Bobo, W. V., Roy, A., Jayathilake, K., Aygun, C., Elif, E. A., Yağcioğlu, A. E. A., & Small, J. G. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0214 · Cited by 176 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and Tolerability of Asenapine in Acute Schizophrenia
Potkin, S. G., & Cohen, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1004 · Cited by 175 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective Disorder
Simpson, G. M., Glick, I. D., Weiden, P. J., Romano, S. J., & SIU, C. O. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1837 · Cited by 170 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
Peuskens, J., Bech, P., Möller, H., Bale, R., Fleurot, O., & Rein, W. (1999) · Psychiatry Research · doi:10.1016/s0165-1781(99)00075-x · Cited by 170 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression
Suppes, T. M., Datto, C. J., Minkwitz, M. C., Nordenhem, A., Walker, C., & Darko, D. F. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.10.007 · Cited by 170 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study
Keck, P. E., Orsulak, P. J., Cutler, A. J., Sanchez, R., Torbeyns, A. F., Marcus, R. N., McQuade, R. D., & Carson, W. H. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.05.014 · Cited by 169 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine Versus Placebo in the Treatment of Borderline Personality Disorder
Bogenschutz, M. P., & Nurnberg, H. G. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0118 · Cited by 168 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Thomas, S., Capuano, G. A., Rosenheck, R. A., Keefe, R. S. E., Miller, A. L., Belz, I., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.415 · Cited by 168 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Association Between Early and Rapid Weight Gain and Change in Weight Over One Year of Olanzapine Therapy in Patients with Schizophrenia and Related Disorders
Kinon, B. J., Kaiser, C. J., Ahmed, S., Rotelli, M. D., & Kollack‐Walker, S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000161501.65890.22 · Cited by 164 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial
McIntyre, R. S., Cohen, M., Zhao, J., Alphs, L. D., Macek, T. A., & Panagides, J. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.12.028 · Cited by 162 · see citing works
A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia
Pandina, G., Lane, R., Gopal, S., Gassmann-Mayer, C., Hough, D. W., Remmerie, B. M. M., & Simpson, G. M. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.008 · Cited by 162 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Obesity, serious mental illness and antipsychotic drugs
Holt, R. I. G., & Peveler, R. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01038.x · Cited by 161 · cited 2× · see citing works
“In SMI patients, overweight and obesity are more prevalent compared to the general population [9], whilst risk of developing cardiovascular diseases is substantially increased [9,10].”
Background
Olanzapine in the treatment of post-traumatic stress disorder: a pilot study
Butterfield, M. I., Becker, M. E., Connor, K. M., Sutherland, S. M., Churchill, L. E., & Davidson, J. R. T. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200107000-00003 · Cited by 160 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and Tolerability of Oral Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia
Meltzer, H. Y., Bobo, W. V., Nuahmah, I. F., Lane, R., Hough, D. W., Kramer, M. L., & Eerdekens, M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0515 · Cited by 158 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Managing Weight Gain and Metabolic Issues in Patients Treated With Atypical Antipsychotics
Henderson, D. C. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0208e04 · Cited by 158 · cited 1× · see citing works
“Overweight and particularly obesity predicts cardiovascular risk, metabolic syndrome (MS) and diabetes mellitus type 2 (DM-II) [1–5] as well as an increased risk for cancer [6,7].”
Background
Olanzapine in the Treatment of Pathological Gambling
McElroy, S. L., Nelson, E. B., Welge, J. A., Kaehler, L. A., & Keck, P. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0314 · Cited by 157 · see citing works
Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
Leucht, S., Kissling, W., & Davis, J. M. (2009) · Psychological Medicine · doi:10.1017/s0033291709005455 · Cited by 156 · cited 1× · see citing works
“Particularly clozapine and olanzapine were associated with severe weight gain, whereas aripiprazole and ziprasidone appeared almost weight neutral [5,20,23,24,26–31].”
Background
A 28-Week Comparison of Ziprasidone and Haloperidol in Outpatients With Stable Schizophrenia
Hirsch, S. R., Kissling, W., Bäuml, J., Power, A., & O'Connor, R. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0609 · Cited by 152 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease
Deyn, P. P. D., Jeste, D. V., Swanink, R., Kostic, D., Breder, C. D., Carson, W. H., & Iwamoto, T. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000178415.22309.8f · Cited by 150 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever
Kluge, M., Schuld, A., Schacht, A., Himmerich, H., Dalal, M. A., Wehmeier, P. M., Hinze-Selch, D., Kraus, T., Dittmann, R. W., & Pollmächer, T. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.08.016 · Cited by 146 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression
Ballenger, J. C. (2011) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/j.ypsy.2010.10.088 · Cited by 146 · see citing works
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine
Chrzanowski, W., Marcus, R. N., Torbeyns, A. F., Nyilas, M., & McQuade, R. D. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0564-3 · Cited by 145 · see citing works
A Randomized, Double-Blind, Placebo-Controlled Trial of Olanzapine in the Treatment of Trichotillomania
Ameringen, M. V., Mancini, C., Patterson, B. A., Bennett, M., & Oakman, J. M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05114gre · Cited by 145 · see citing works
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Bitter, I., Dossenbach, M. R. K., Brook, S., Feldman, P. D., Metcalfe, S., Gagiano, C. A., Füredi, J., Bartkó, G., Janka, Z., Bánki, C. M., et al. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.033 · Cited by 145 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Results of phase 3 of the CATIE schizophrenia trial
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Thomas, S., Swartz, M. S., Keefe, R. S. E., Miller, A. L., Rosenheck, R. A., & Hsiao, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.10.011 · Cited by 141 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study
Bobes, J., Rejas, J., García-García, M., Rico‐Villademoros, F., García‐Portilla, M. P., Fernández, I., & Hernández, G. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00431-0 · Cited by 140 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial
Revicki, D. A., Genduso, L. A., Hamilton, S. H., Ganoczy, D. A., & Beasley, C. M. (1999) · Quality of Life Research · doi:10.1023/a:1008958925848 · Cited by 137 · see citing works
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis
Strassnig, M., Miewald, J. M., Keshavan, M. S., & Ganguli, R. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.02.024 · Cited by 135 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Dementia with Lewy bodies: diagnosis and management
Barber, R., Panikkar, A., & McKeith, I. G. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200112)16:1+ · Cited by 135 · see citing works
A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine
Newcomer, J. W., Campos, J. A. D. O., Marcus, R. N., Breder, C. D., Berman, R., Kerselaers, W., L'Italien, G. J., Nys, M., Carson, W. H., & McQuade, R. D. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0702 · Cited by 130 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of Switching to Ziprasidone for Stable but Symptomatic Outpatients With Schizophrenia
Weiden, P. J., Simpson, G. M., Potkin, S. G., & O’Sullivan, R. L. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0514 · Cited by 130 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Comparison of Olanzapine and Risperidone in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients With Dementia
Deberdt, W. G., Dysken, M. W., Rappaport, S. A., Feldman, P. D., Young, C. A., Hay, D. P., Lehman, D. L., Dossenbach, M. R. K., Degenhardt, E. K., & Breier, A. F. (2005) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200508000-00012 · Cited by 129 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Hyperglycemic Clamp Assessment of Insulin Secretory Responses in Normal Subjects Treated with Olanzapine, Risperidone, or Placebo
Sowell, M. O., Mukhopadhyay, N. D., Cavazzoni, P. A., Shankar, S. S., Steinberg, H. O., Breier, A. F., Beasley, C. M., & Dananberg, J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8599 · Cited by 129 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results
Haro, J. M., Suarez, D. L., Novick, D., Brown, J., Usall, J., & Naber, D. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.09.005 · Cited by 129 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Long-term use of quetiapine in elderly patients with psychotic disorders
Tariot, P. N., Salzman, C., Yeung, P. P., Pute, J., & Rak, I. W. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80085-5 · Cited by 128 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Metabolic risk during antipsychotic treatment
Newcomer, J. W. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.12.003 · Cited by 125 · cited 1× · see citing works
“Amisulpride, aripiprazole and ziprasidone were weight neutral and may even result in some weight reduction [52].”
Background
Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study
Schulz, S. C., Zanarini, M. C., BATEMAN, A. W., Bohus, M., Detke, H. C., Trzaskoma, Q., Tanaka, Y., Lin, D., Deberdt, W. G., & Corya, S. A. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037903 · Cited by 125 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia
Lauriello, J., Lambert, T., Andersen, S., Lin, D., Taylor, C. C., & McDonnell, D. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0512 · Cited by 120 · see citing works
Amisulpride vs. Risperidone in Chronic Schizophrenia Results of a 6-month Double-blind Study
Sechter, D. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00375-5 · Cited by 120 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Rock, S. L., Woolson, S., Tohen, M. F., Tollefson, G. D., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.022 · Cited by 120 · see citing works
A Preliminary Study of Risperidone in the Treatment of Posttraumatic Stress Disorder Related to Childhood Abuse in Women
Reich, D. B., Winternitz, S., Hennen, J. A., Watts, T., & Stanculescu, C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1204 · Cited by 119 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia
Hosojima, H., Togo, T., Odawara, T., Hasegawa, K., Miura, S., Kato, Y., Kanai, A., Kase, A., Uchikado, H., & Hirayasu, Y. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056647 · Cited by 118 · see citing works
Olanzapine increases plasma ghrelin level in patients with schizophrenia
Murashita, M. M., Kusumi, I., Inoue, T., Takahashi, Y., Hosoda, H., Kangawa, K., & Koyama, T. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2004.05.008 · Cited by 116 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies
ller, H.-J. R. M., Llorca, P., Sacchetti, E., Martin, S. D., Medori, R., & Parellada, E. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200505000-00001 · Cited by 115 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole for the Treatment of Psychosis in Nursing Home Patients with Alzheimer Disease
Streim, J. E., Porsteinsson, A. P., Breder, C. D., Swanink, R., Marcus, R. N., McQuade, R. D., & Carson, W. H. (2008) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318165db77 · Cited by 114 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight gain in antipsychotic-naive patients: a review and meta-analysis
Tarricone, I., Gozzi, B. F., Serretti, A., Grieco, D., & Berardi, D. (2009) · Psychological Medicine · doi:10.1017/s0033291709990407 · Cited by 112 · cited 8× · see citing works
“Second, BMI increases after first exposure to AP from more than 1 BMI point after 4–8 weeks, to almost 4 BMI points after 24–48 weeks [26].”
BackgroundMethodResultInfluential
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study
Kerwin, R. W., Millet, B., Herman, E., Bánki, C. M., Lublin, H., Pans, M., Hanssens, L., L'Italien, G. J., McQuade, R. D., & Beuzen, J. N. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.03.002 · Cited by 111 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
An Open-Label Study of the Treatment Efficacy of Olanzapine for Tourette's Disorder
Budman, C. L., GAYER, A. I., LESSER, M. L., Shi, Q., & BRUUN, R. D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0412 · Cited by 111 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial
Gäebel, W., Schreiner, A., Bergmans, P., de Arce, R., Rouillon, F., Cordes, J., Eriksson, L., & Smeraldi, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.111 · Cited by 111 · see citing works
Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid‐cycling disease course: a randomized, double‐blind, placebo‐controlled study
Vieta, E., Calabrese, J., Goikolea, J., Raines, S. R., Macfadden, W., & for the BOLDER Study Group (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00479.x · Cited by 110 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Weisler, R. H., Joyce, J. M., McGill, L., Lazarus, A. L., Szamosi, J., Eriksson, H., & Moonstone Study Group (2009) · CNS Spectrums · doi:10.1017/s1092852900020307 · Cited by 109 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia
Schulz, S. C., Camlin-Shingler, K., Berry, S. A., & Jesberger, J. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00128-6 · Cited by 109 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study
Young, A. H., Oren, D. A., Lowy, A., McQuade, R. D., Marcus, R. N., Carson, W. H., Spiller, N. H., Torbeyns, A. F., & Sanchez, R. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.049965 · Cited by 109 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Randomized Controlled Trial of Olanzapine Versus Haloperidol in the Treatment of Primary Negative Symptoms and Neurocognitive Deficits in Schizophrenia
Lindenmayer, J., Khan, A., Iskander, A., Abad, M. T., & Parker, B. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0303 · Cited by 108 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia
Lahti‐Pulkkinen, M., Tiihonen, J., Wildgust, H. J., Beary, M., Hodgson, R. E., Kajantie, E., Osmond, C., Räikkönen, K., & Eriksson, J. G. (2012) · Psychological Medicine · doi:10.1017/s0033291712000396 · Cited by 106 · cited 1× · see citing works
“People with a diagnosis of schizophrenia have a 2–3 times increased standard mortality ratio, for all causes of death [11–13].”
Background
A 12-Week Randomized Clinical Trial to Evaluate Metabolic Changes in Drug-Naive, First-Episode Psychosis Patients Treated With Haloperidol, Olanzapine, or Risperidone
Pérez‐Iglesias, R., & Crespo‐Facorro, B. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1113 · Cited by 104 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Single-Blind, Randomized Trial Comparing Quetiapine and Haloperidol in the Treatment of Tardive Dyskinesia
Emsley, R. A., Turner, H. J., Schronen, J., Botha, K., Smit, R., & Oosthuizen, P. P. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0516 · Cited by 104 · see citing works
A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia
Gopal, S., Vijapurkar, U., Lim, P., Ma, M., Eerdekens, M., & Hough, D. W. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110372817 · Cited by 103 · see citing works
A Double-Blind, Randomized Comparative Study of Aripiprazole and Olanzapine in Patients with Schizophrenia
Fleischhacker, W. W., McQuade, R. D., Marcus, R. N., Archibald, D., Swanink, R., & Carson, W. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.07.033 · Cited by 103 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Asenapine for long-term treatment of bipolar disorder: A double-blind 40-week extension study
McIntyre, R. S., Cohen, M., Zhao, J., Alphs, L. D., Macek, T. A., & Panagides, J. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.04.005 · Cited by 102 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Naturalistic Comparison of Clozapine, Risperidone, and Olanzapine in the Treatment of Bipolar Disorder
Guille, C., Sachs, G. S., & Ghaemi, S. N. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0907 · Cited by 102 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Randomized double blind comparison of olanzapine vs. clozapine on subjective well‐being and clinical outcome in patients with schizophrenia
Naber, D., Riedel, M. J., Klimke, A., Vorbach, E.-U., Lambert, M., Kühn, K. ‐., Bender, S., Bandelow, B., Lemmer, W., Moritz, S., et al. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00486.x · Cited by 102 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Thomas, S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., DAVIS, C. E., Severe, J. B., et al. (2006) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.4.4.539 · Cited by 102 · see citing works
International Multisite Double-Blind Trial of the Atypical Antipsychotics Risperidone and Olanzapine in 175 Elderly Patients With Chronic Schizophrenia
Jeste, D. V., Barak, Y., Madhusoodanan, S., Grossman, F., & Gharabawi, G. M. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200311000-00008 · Cited by 102 · see citing works
How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins
Starrenburg, F. C. J., & Bogers, J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.001 · Cited by 100 · cited 2× · see citing works
“In addition, certain diagnoses like schizophrenia and to lesser extent bipolar disorder have been associated with a higher level of metabolic dysregulation [32] and weight gain may be more substantial in this group of patients.”
Background
Long-Term Olanzapine Therapy in the Treatment of Bipolar I Disorder
Sanger, T. M., Grundy, S. L., Gibson, P. J., Namjoshi, M. A., Greaney, M. G., & Tohen, M. F. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0410 · Cited by 99 · see citing works
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20mg/day for the treatment of patients with acute exacerbations of schizophrenia
McEvoy, J. P., Daniel, D. G., Carson, W. H., McQuade, R. D., & Marcus, R. N. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.05.002 · Cited by 96 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder
Kinon, B. J., Volavka, J., Stauffer, V. L., Edwards, S., Liu‐Seifert, H., Chen, L., Adams, D. H., Lindenmayer, J., McEvoy, J. P., Buckley, P. F., et al. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817e63a5 · Cited by 96 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine Versus Risperidone in the Treatment of Manic or Mixed States in Bipolar I Disorder
Perlis, R. H., Baker, R. W., Zarate, C. A., Brown, E. B., Schuh, L. M., Jamal, H. H., & Tohen, M. F. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1112 · Cited by 95 · see citing works
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6‐month double‐blind controlled clinical trial
Lecrubier, Y., Quintin, P., Bouhassira, M., Perrin, E., & Lancrenon, S. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00887.x · Cited by 95 · see citing works
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization
Potkin, S. G., Gharabawi, G. M., Greenspan, A. J., Mahmoud, R. A., Kosik‐Gonzalez, C., Rupnow, M. F. T., Bossie, C. A., Davidson, M., Burtea, V., & ZHU, Y. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.027 · Cited by 94 · see citing works
Safety Profile of Iloperidone
Weiden, P. J., Cutler, A. J., Polymeropoulos, M. H., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181694f5a · Cited by 94 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis
Emsley, R. A., Medori, R., Koen, L., Oosthuizen, P., Niehaus, D. J. H., & Rabinowitz, J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318167269d · Cited by 93 · see citing works
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
Jones, B. S., Basson, B. R., Walker, D. J., Crawford, A. M., & Kinon, B. J. (2001) · PubMed · Cited by 89 · see citing works
Quetiapine: An Effective Antipsychotic in First-Episode Schizophrenia Despite Only Transiently High Dopamine-2 Receptor Blockade
Tauscher‐Wisniewski, S., Kapur, S., Tauscher, J. T., Jones, C., Daskalakis, Z. J., Papatheodorou, G. N., Epstein, I., Christensen, B. K., & Zipursky, R. B. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1106 · Cited by 88 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and Safety of Aripiprazole in the Acute Treatment of Schizophrenia in Chinese Patients With Risperidone as an Active Control
Chan, H., Lin, W., Lin, S., Hwang, T., Su, T.-P. T., Chiang, S.-C., & Hwu, H. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0104 · Cited by 88 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Obesity in Patients With Severe Mental Illness
McElroy, S. L. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.7075su1c.03 · Cited by 88 · cited 1× · see citing works
“Patients with SMI have an increased risk for metabolic problems like obesity [9,53,54].”
Background
A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse
Beasley, C. M., Sutton, V. K., Hamilton, S. H., Walker, D. J., Dossenbach, M. R. K., Taylor, C. C., Alaka, K., Bykowski, D., & Tollefson, G. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095348.32154.ec · Cited by 87 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia
Kim, D. H., Maneen, M. J., & Stahl, S. M. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.020 · Cited by 87 · cited 1× · see citing works
“AP medication induces changes in appetite and food intake, most likely because of interaction with serotonergic [32], histaminergic [33] and dopaminergic [34] neurotransmitter systems inducing increase in appetite and food intake.”
Background
The impact upon extra‐pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia
Ritchie, C. W., Chiu, E., Harrigan, S., Hall, K., Hassett, A. M., Macfarlane, S., Mastwyk, M., O’Connor, D., Opie, J., & Ames, D. J. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.862 · Cited by 87 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Diabetes and schizophrenia – effect of disease or drug? Results from a randomized, double‐blind, controlled prospective study in first‐episode schizophrenia
Saddichha, S., Manjunatha, N., Ameen, S., & Akhtar, S. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01158.x · Cited by 87 · see citing works
Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder
Schoemaker, J. H., Naber, D., Vrijland, P., Panagides, J., & Emsley, R. (2010) · Pharmacopsychiatry · doi:10.1055/s-0030-1248313 · Cited by 84 · see citing works
A 24-Week Randomized Study of Olanzapine Versus Ziprasidone in the Treatment of Schizophrenia or Schizoaffective Disorder in Patients with Prominent Depressive Symptoms
Kinon, B. J., Lipkovich, I. A., Edwards, S. B., Adams, D. H., Ascher‐Svanum, H., & Siris, S. G. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000204137.82298.06 · Cited by 84 · see citing works
Six-Month, Blinded, Multicenter Continuation Study of Ziprasidone Versus Olanzapine in Schizophrenia
Simpson, G. M., Weiden, P. J., Pigott, T., Murray, S., SIU, C. O., & Romano, S. J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1535 · Cited by 83 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies
Emsley, R. A., Berwaerts, J., Eerdekens, M., Kramer, M. L., Lane, R., Lim, P., Hough, D., & Palumbo, J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328314e1f3 · Cited by 83 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Dose Comparison of Olanzapine for the Treatment of Borderline Personality Disorder
Zanarini, M. C., Schulz, S. C., Detke, H. C., Tanaka, Y., Zhao, F., Lin, D., Deberdt, W. G., Kryzhanovskaya, L. A., & Corya, S. A. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04138yel · Cited by 83 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder
Keks, N. A., Ingham, M., Khan, A., & Karcher, K. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.017020 · Cited by 83 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia
Kinon, B. J., Hill, A. L., Liu, H., & Kollack‐Walker, S. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003389 · Cited by 82 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs
Theisen, F., Gebhardt, S., Haberhausen, M., Heinzel‐Gutenbrunner, M., Wehmeier, P. M., Krieg, J.-C., hnau, W. K., Schmidtke, J., Remschmidt, H., & Hebebrand, J. (2005) · Psychiatric Genetics · doi:10.1097/00041444-200512000-00011 · Cited by 82 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of second generation antipsychotics: A systematic review of randomized trials
Johnsen, E., & Jørgensen, H. A. (2008) · BMC Psychiatry · doi:10.1186/1471-244x-8-31 · Cited by 82 · cited 1× · see citing works
“Particularly clozapine and olanzapine were associated with severe weight gain, whereas aripiprazole and ziprasidone appeared almost weight neutral [5,20,23,24,26–31].”
Background
Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone
Lasser, R. A., Bossie, C. A., Gharabawi, G. M., & Turner, M. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2003.11.007 · Cited by 81 · see citing works
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study☆
Bortnick, B., El-Khalili, N., Banov, M. D., Adson, D. E., Datto, C. J., Raines, S. R., Earley, W. R., & Eriksson, H. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.031 · Cited by 80 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Randomized Placebo-Controlled Trial of Asenapine for the Prevention of Relapse of Schizophrenia After Long-Term Treatment
Kane, J. M., Mackle, M., Snow‐Adami, L., Zhao, J., Szegedi, A., & Panagides, J. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06306 · Cited by 80 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
International Multisite Double-Blind Trial of the Atypical Antipsychotics Risperidone and Olanzapine in 175 Elderly Patients With Chronic Schizophrenia
Jeste, D. V. (2003) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.11.6.638 · Cited by 80 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications
Beary, M., Hodgson, R., & Wildgust, H. J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112440512 · Cited by 79 · cited 1× · see citing works
“Overweight and particularly obesity predicts cardiovascular risk, metabolic syndrome (MS) and diabetes mellitus type 2 (DM-II) [1–5] as well as an increased risk for cancer [6,7].”
Background
Clinical outcome and olanzapine plasma levels in acute schizophrenia
Mauri, M. C., Steinhilber, C. P. C., Marino, R., Invernizzi, E., Fiorentini, A., Cerveri, G., Baldi, M., & Barale, F. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.09.009 · Cited by 76 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight Considerations in Psychotropic Drug Prescribing and Switching
Hasnain, M., & Vieweg, W. R. (2013) · Postgraduate medicine · doi:10.3810/pgm.2013.09.2706 · Cited by 75 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and Tolerability of Ziprasidone Versus Risperidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Addington, D. E., Pantelis, C., Dineen, M., Benattia, I., & Romano, S. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1207 · Cited by 75 · see citing works
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
Ascher‐Svanum, H., Stensland, M. D., Zhao, Z., & Kinon, B. J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-3 · Cited by 74 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Safety and Efficacy of Long-Acting Risperidone in Schizophrenia
Lindenmayer, J., Eerdekens, E., Berry, S. A., & Marielle, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0809 · Cited by 74 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
The Apparent Effects of Ziprasidone on Plasma Lipids and Glucose
Kingsbury, S. J., Fayek, M., Trufasiu, D., Zada, J., & Simpson, G. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0507 · Cited by 73 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol
KRAKOWSKI, M. I., Czobor, P., & Citrome, L. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.02.006 · Cited by 73 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine vs. other antipsychotics in actual out‐patient settings: six months tolerability results from the European Schizophrenia Out‐patient Health Outcomes study
Lambert, M., Haro, J. M., Novick, D., Edgell, E. T., Kennedy, L., Ratcliffe, M., & Naber, D. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00451.x · Cited by 72 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Strategies for Switching From Conventional Antipsychotic Drugs or Risperidone to Olanzapine
Kinon, B. J., Basson, B. R., Gilmore, J. A., Malcolm, S. K., & Stauffer, V. L. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1105 · Cited by 70 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Quetiapine for the treatment of bipolar mania in older adults
Sajatovic, M., Calabrese, J. R., & Mullen, J. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00614.x · Cited by 70 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapineversushaloperidol in the treatment of schizoaffective disorder
Trân, P. V., Tollefson, G. D., Sanger, T. M., Lu, Y., Berg, P. H., & Beasley, C. M. (1999) · The British Journal of Psychiatry · doi:10.1192/bjp.174.1.15 · Cited by 69 · see citing works
Effects of long-term treatment with antipsychotics on serum leptin levels
Herrán, A., García‐Unzueta, M. T., Amado, J., Maza, M. T. D. L., Álvarez, C. F., & Vázquez‐Barquero, J. L. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.1.59 · Cited by 69 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety
Sheehan, D. V., McElroy, S. L., Harnett-Sheehan, K., Keck, P. E., Janavs, J., Rogers, J., Gonzalez, R., Shivakumar, G., & Suppes, T. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.005 · Cited by 69 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Use of Ziprasidone in Parkinsonian Patients With Psychosis
Gómez‐Esteban, J. C., Zarranz, J. J., Velasco, F., Lezcano, E., Lachen, M. C., Rouco, I., Bárcena, J., Boyero, S., Ciordia, R., & Allue, I. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000164297.91643.ff · Cited by 68 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Quetiapine Alone and Added to a Mood Stabilizer for Serious Mood Disorders
Sajatovic, M., Brescan, D. W., Perez, D. E., DiGiovanni, S. K., Hattab, H., Belton, J., & Bingham, C. R. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0911 · Cited by 68 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
The Early Effect of Olanzapine and Risperidone on Insulin Secretion in Atypical-naïve Schizophrenic Patients
Chiu, C.-C., Chen, K.-P., Liu, H.-C., & Lu, M. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000237947.80764.d9 · Cited by 67 · see citing works
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling
Sanger, T. M., Tohen, M. F., Vieta, E., Dünner, D. L., Bowden, C. L., Calabrese, J. R., Feldman, P. D., Jacobs, T. G., & Breier, A. F. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00334-8 · Cited by 67 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A 28-Week, Randomized, Double-Blind Study of Olanzapine Versus Aripiprazole in the Treatment of Schizophrenia
Kane, J. M., Osuntokun, O. O., Kryzhanovskaya, L. A., Xu, W. R., Stauffer, V. L., Watson, S. B., & Breier, A. F. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04421 · Cited by 66 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study
Sacchetti, E., Galluzzo, A., Valsecchi, P., Romeo, F., Gorini, B., & Warrington, L. E. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.02.017 · Cited by 66 · see citing works
Early Predictors of Substantial Weight Gain in Bipolar Patients Treated with Olanzapine
Lipkovich, I. A., Citrome, L., Perlis, R. H., Deberdt, W. G., Houston, J., AHL, J. S. B., & Hardy, T. A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000219916.88810.1c · Cited by 65 · see citing works
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
Kane, J. M., Khanna, S., Rajadhyaksha, S., & Giller, E. L. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000182114.65134.81 · Cited by 65 · see citing works
Comparison of Quetiapine and Risperidone in the Treatment of Schizophrenia
Zhong, K., Sweitzer, D. E., Hamer, R. M., & Lieberman, J. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0712 · Cited by 65 · cited 1× · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”

Flagged first, then by citations

Research works printed but not linked: 1

[163]Chue P (2005) Study of long-term quetiapine treatment. The journal of applied research 5: 246– 252.

Sorted by citations

Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity
Hampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389 · see citing works
Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline
Styne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2573 · Cited by 1,322 · see citing works
“Furthermore, clinicians should obtain a history of second-generation antipsychotics use, such as clozapine, risperidone, olan-zapine, and quetiapine, because of their association with weight gain (52, 53).”
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877 · see citing works
“Where possible, medicines with the least risk of weight gain should be selected (Bak et al., 2014).”
Background
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820 · see citing works
Antipsychotic medication in schizophrenia: a review
Lally, J., & MacCabe, J. H. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv017 · Cited by 515 · see citing works
“The most dramatic weight gain is seen in antipsychotic naïve patients over the first 6 weeks of treatment and for the majority, those with initial weight gain did not lose that weight thereafter, even after switching to more weight-neutral antipsychotics.(14) SGAs such as aripiprazole, lurasidone and asenapine have a…”
Background
Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
Dayabandara, M., Hanwella, R., Ratnatunga, S. S., Seneviratne, S., Suraweera, C. U., & de Silva, V. A. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s113099 · Cited by 377 · see citing works
“An interesting finding described by Bak et al was that weight increased more significantly during the period beyond 38 weeks than within the first 6 weeks for olanzapine and FGA group and for olanzapine alone in antipsychoticnaïve group.(13) Factors associated with rapid weight gain in the initial period were younger…”
BackgroundMethod
Obstructive Sleep Apnea and Psychiatric Disorders: A Systematic Review
Gupta, M. A., & Simpson, F. C. (2015) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.4466 · Cited by 365 · see citing works
“85–87 The association between obesity and psychiatric medication is well known, 79,82,85,87,88 but the direct effects of these drugs on the upper airway and breathing during sleep are important factors.”
Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
Manu, P., Dima, L., Shulman, M., Vancampfort, D., Hert, M. D., & Correll, C. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12445 · Cited by 281 · see citing works
Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses
Henderson, D. C., Vincenzi, B., Andrea, N. V., Ulloa, M., & Copeland, P. M. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00115-7 · Cited by 288 · see citing works
Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications
Rosenblat, J., & McIntyre, R. (2017) · Brain Sciences · doi:10.3390/brainsci7110144 · Cited by 258 · see citing works
ACOG Clinical Practice Guideline No. 5: Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum
ACOG Committee on Clinical Practice Guidelines–Obstetrics (2023) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000005202 · Cited by 252 · see citing works
“( STRONG REC-OMMENDATION, MODERATE-QUALITY EVIDENCE) Many of the existing antipsychotic medications are associated with metabolic side effects, including weight gain (172) and metabolic syndrome (173), including insulin resistance.”
Background
The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta‐analysis
Stubbs, B., Vancampfort, D., Hert, M. D., & Mitchell, A. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12439 · Cited by 232 · see citing works
Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.
de Silva, V. A., Suraweera, C., Ratnatunga, S. S., Dayabandara, M., Wanniarachchi, N., & Hanwella, R. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1049-5 · Cited by 227 · see citing works
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1713091 · Cited by 216 · see citing works
Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness
Mazereel, V., Detraux, J., Vancampfort, D., van Winkel, R., & Binder, M. D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.573479 · Cited by 205 · see citing works
Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects
Siafis, S., Tzachanis, D., Samara, M. T., & Papazisis, G. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170630163616 · Cited by 186 · see citing works
Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review
Wagner, E. M., Siafis, S., Fernando, P., Falkai, P., Honer, W. G., Roeh, A., Siskind, D. J., Leucht, S., & Hasan, A. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01613-2 · Cited by 191 · see citing works
Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
Ward, K., & Citrome, L. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s169369 · Cited by 181 · see citing works
Diabetes mellitus and severe mental illness: mechanisms and clinical implications
Holt, R. I. G., & Mitchell, A. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.203 · Cited by 181 · see citing works
Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications
Tek, C., Kuçukgoncu, S., Guloksuz, S., Woods, S. W., Srihari, V., & Annamalai, A. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12251 · Cited by 161 · see citing works
“Randomized clinical trials(19,20) provided some support for this line of thinking as well as a recent meta-analysis which showed that medication-naïve patients, including first episode but mostly other diagnoses such as post-traumatic stress disorder, depression and dementia, gain weight on first-generation AP agents…”
Result
The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity
Speyer, H., Christian Brix Nørgaard, H., Birk, M., Karlsen, M., Storch Jakobsen, A., Pedersen, K., Hjorthøj, C., Pisinger, C., Gluud, C., Mors, O., et al. (2016) · World Psychiatry · doi:10.1002/wps.20318 · Cited by 153 · see citing works
Early Intervention for Psychosis
Iyer, S. N., Jordan, G., MacDonald, K., Joober, R., & MALLA, A. K. (2015) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000288 · Cited by 146 · see citing works
Risk Factors for Unhealthy Weight Gain and Obesity among Children with Autism Spectrum Disorder
Dhaliwal, K. K., Orsso, C. E., Richard, C., Haqq, A. M., & Zwaigenbaum, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133285 · Cited by 149 · see citing works
Acute variations of cytokine levels after antipsychotic treatment in drug-naïve subjects with a first-episode psychosis: A meta-analysis
Capuzzi, E., Bartoli, F., Crocamo, C., Clerici, M., & Carrà, G. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.03.003 · Cited by 139 · see citing works
“Indeed, almost all antipsychotics, also after short-term treatment, raise the risk of metabolic abnormalities (Bak et al., 2014; Tek et al., 2016),”
Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
Lally, J., Gaughran, F., Timms, P. W., & Curran, S. R. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s115741 · Cited by 131 · see citing works
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials
Wu, H., Siafis, S., Hamza, T., Schneider‐Thoma, J., Davis, J. M., Salanti, G., & Leucht, S. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac001 · Cited by 131 · see citing works
Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota
Kao, A. C.-C., Spitzer, S., Anthony, D. C., Lennox, B., & Burnet, P. W. J. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0116-8 · Cited by 128 · see citing works
Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis
Lambert, A., Parretti, H. M., Pearce, E., Price, M. J., Riley, M. R., Ryan, R. P., Tyldesley‐Marshall, N., Avşar, T. S., Matthewman, G., Lee, A., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003960 · Cited by 131 · see citing works
The Relationship Between the Serotonin Metabolism, Gut-Microbiota and the Gut-Brain Axis
Stasi, C., Sadalla, S., & Milani, S. (2019) · Current Drug Metabolism · doi:10.2174/1389200220666190725115503 · Cited by 127 · see citing works
Weight gain and metabolic changes during treatment with antipsychotics and antidepressants
Himmerich, H., Minkwitz, J., & Kirkby, K. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150623092031 · Cited by 122 · see citing works
Side effect burden of antipsychotic drugs in real life – Impact of gender and polypharmacy
Iversen, T., Steen, N. E., Dieset, I., Hope, S., Mørch, R. H., Gardsjord, E. S., Jørgensen, K. N., Melle, I. S., Andreassen, O. A., Molden, E., et al. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.11.004 · Cited by 120 · see citing works
“A meta-analysis from 2014 on antipsychotic-induced weight gain in clinical trials similarly concluded that most antipsychotics result in weight gain at an early time and increase with prolonged use, and drug naïve patients are especially deferred (Bak et al., 2014).”
Background
Cost Savings From Utilization of an Ambulatory Surgery Center for Orthopaedic Day Surgery
Fabricant, P. D., Seeley, M. A., Rozell, J. C., Fieldston, E. S., Flynn, J. M. “., Wells, L. M., & Ganley, T. J. (2016) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-15-00751 · Cited by 118 · see citing works
The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment
Raben, A., Marshe, V. S., Chintoh, A. F., Gorbovskaya, I., Müller, D. J., & Hahn, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00741 · Cited by 114 · see citing works
Metabolic side effects in persons with schizophrenia during mid‐ to long‐term treatment with antipsychotics: a network meta‐analysis of randomized controlled trials
Burschinski, A., Schneider-Thoma, J., Chiocchia, V., Schestag, K., Wang, D., Siafis, S., Bighelli, I., Wu, H., Hansen, W.-P., Priller, J., et al. (2023) · World Psychiatry · doi:10.1002/wps.21036 · Cited by 102 · see citing works
Antipsychotic medication for women with schizophrenia spectrum disorders
Brand, B. A., Haveman, Y. R. A., de Beer, F., de Boer, J. N., Dazzan, P., & Sommer, I. E. (2021) · Psychological Medicine · doi:10.1017/s0033291721004591 · Cited by 106 · see citing works
“Increased appetite and food intake can be a result of the antagonistic effect of antipsychotics on several neurotransmitter systems (i.e. serotonergic, histaminergic and dopaminergic) (Bak, Fransen, Janssen, Van Os, & Drukker, 2014).”
Effects of atypical antipsychotic treatment and resistant starch supplementation on gut microbiome composition in a cohort of patients with bipolar disorder or schizophrenia
Flowers, S. A., Baxter, N. T., Ward, K. M., Kraal, A. Z., McInnis, M. G., Schmidt, T. M., & Ellingrod, V. L. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2214 · Cited by 100 · see citing works
Food for Thought: Reward Mechanisms and Hedonic Overeating in Obesity
Lee, P. C., & Dixon, J. B. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0280-9 · Cited by 97 · see citing works
A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia
Malan‐Müller, S., Kilian, S., van den Heuvel, L. L., Bardien, S., Asmal, L., Warnich, L., Emsley, R. A., Hemmings, S. M. J., & Seedat, S. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.011 · Cited by 98 · see citing works
Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome
Skonieczna‐Żydecka, K., Łoniewski, I., Misera, A., Stachowska, E., Maciejewska, D., Marlicz, W. M., & Galling, B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5102-6 · Cited by 101 · see citing works
“These changes emerge even after short exposure and increase with cumulative dosages, and differ between agents (Bak et al. 2014).”
Background
Health benefits, safety and cost of physical activity interventions for mental health conditions: A meta-review to inform translation efforts
Czosnek, L., Lederman, O., Cormie, P., Zopf, E., Stubbs, B., & Rosenbaum, S. (2019) · Mental Health and Physical Activity · doi:10.1016/j.mhpa.2018.11.001 · Cited by 94 · see citing works
Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes
Park, Y., Hernández–Dı́az, S., Bateman, B. T., Cohen, J. M., Desai, R. J., Patorno, E., Glynn, R. J., Cohen, L. S., Mogun, H., & Huybrechts, K. F. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17040393 · Cited by 90 · see citing works
Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives
Singh, R., Bansal, Y., Medhi, B., & Kuhad, A. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.12.003 · Cited by 90 · see citing works
Clozapine Underutilization in the Treatment of Schizophrenia
Bogers, J. P. A. M., Schulte, P. F. J., van Dijk, D., Bakker, E., & Cohen, D. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000478 · Cited by 86 · see citing works
Obesity in adults with 22q11.2 deletion syndrome
Voll, S. L., Boot, E., Butcher, N. J., Cooper, S., Heung, T., Chow, E. W. C., Silversides, C. K., & Bassett, A. S. (2016) · Genetics in Medicine · doi:10.1038/gim.2016.98 · Cited by 86 · see citing works
Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies
Burghardt, K. J., Seyoum, B., Mallisho, A., Burghardt, P. R., Kowluru, R. A., & Yi, Z. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.01.004 · Cited by 82 · see citing works
“Many of the AAPs cause significant weight gain and insulin resistance with extended treatment yet, not all AAPs cause metabolic dysfunction to the same degree (5, 12, 13).”
Influential
Overweight and Obesity in Children with Autism Spectrum Disorder (ASD): A Critical Review Investigating the Etiology, Development, and Maintenance of this Relationship
Matheson, B. E., & Douglas, J. M. (2017) · Review Journal of Autism and Developmental Disorders · doi:10.1007/s40489-017-0103-7 · Cited by 81 · see citing works
Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
Jeon, S., & Kim, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102174 · Cited by 82 · see citing works
Antipsychotic Medication Use Among Publicly Insured Pregnant Women in the United States
Park, Y., Huybrechts, K. F., Cohen, J. M., Bateman, B. T., Desai, R. J., Patorno, E., Mogun, H., Cohen, L. S., & Hernández–Dı́az, S. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201600408 · Cited by 78 · see citing works
“The decrease in the use of olanzapine may be explained by the known risk of metabolic side effects, including weight gain (30).”
Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies
Ostuzzi, G., Bighelli, I., So, R., Furukawa, T. A., & Barbui, C. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.010 · Cited by 78 · see citing works
“For weight gain, an increase of more than 7% of the baseline weight or BMI was considered clinically relevant (Bak et al., 2014; Sachs and Guille, 1999); this threshold was used to convert weight scores into number of patientswith clinically relevantweight increase.”
Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis
Siskind, D. J., Gallagher, E., Winckel, K., Hollingworth, S., Kisely, S. R., Firth, J., Correll, C. U., & Marteene, W. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa191 · Cited by 76 · see citing works
Diabetes and Mental Health
Robinson, D. J., Hanson, K., Jain, A. B., Kichler, J. C., Mehta, G., Melamed, O. C., Vallis, M., Bajaj, H. S., Barnes, T., Gilbert, J., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.04.009 · Cited by 73 · see citing works
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
Keks, N. A., Hope, J., Schwartz, D., McLennan, H., Copolov, D., & Meadows, G. N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00718-4 · Cited by 71 · see citing works
Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment
Reynolds, G. P., & McGowan, O. O. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117722987 · Cited by 67 · see citing works
Nutritional Status Affects Cortical Folding: Lessons Learned From Anorexia Nervosa
Bernardoni, F., King, J. A., Geisler, D., Birkenstock, J., Tam, F. I., Weidner, K., Roessner, V., White, T. J. H., & Ehrlich, S. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.05.008 · Cited by 69 · see citing works
Lithium therapy and weight change in people with bipolar disorder: A systematic review and meta-analysis
Gomes‐da‐Costa, S., Marx, W., Corponi, F., Anmella, G., Murru, A., Pons-Cabrera, M. T., Giménez‐Palomo, A., Gutiérrez-Arango, F., Llach, C.-D., Fico, G., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.011 · Cited by 67 · see citing works
Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis
Stubbs, B., Wang, A. K., Vancampfort, D., & Miller, B. J. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.09.026 · Cited by 66 · see citing works
Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
Soria‐Chacartegui, P., Villapalos‐García, G., Zubiaur, P., Abad‐Santos, F., & Koller, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.711940 · Cited by 64 · see citing works
Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications
Fonseka, T. M., Müller, D. J., & Kennedy, S. H. (2016) · Complex Psychiatry · doi:10.1159/000441521 · Cited by 64 · see citing works
Top Ten Tips Palliative Care Clinicians Should Know About Psychopharmacology
Riordan, P. A., Briscoe, J. G., Uritsky, T. J., Jones, C. A., & Webb, J. A. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2019.0106 · Cited by 63 · see citing works
Identifying underlying medical causes of pediatric obesity: Results of a systematic diagnostic approach in a pediatric obesity center
Kleinendorst, L., Abawi, O., van der Voorn, B., Jongejan, M. H. T. M., Brandsma, A. E., Visser, J. A., van Rossum, E. F. C., van der Zwaag, B., Alders, M., Boon, E. M. J., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232990 · Cited by 62 · see citing works
“[13] Furthermore, the guideline mentions only antipsychotics as weight-inducing medication, but we also considered specific antipsychotic or anti-epileptic drugs [37, 38] and prolonged use of corticosteroids [35, 36] as potential cause of obesity in individual patients, but only in the presence of a temporal relations…”
Background
Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives
Chang, S.-C., Goh, K. K., & Lu, M. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i10.696 · Cited by 67 · see citing works
Analysis of gut microbiota and their metabolic potential in patients with schizophrenia treated with olanzapine: results from a six-week observational prospective cohort study
Pełka-Wysiecka, J., Kaczmarczyk, M., Bąba-Kubiś, A., Liśkiewicz, P., Wroński, M., Skonieczna-Żydecka, K., Marlicz, W., Misiak, B., Starzyńska, T., Kucharska-Mazur, J., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101605 · Cited by 59 · see citing works
Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations
Stogios, N., Humber, B. E., Agarwal, S. M., & Hahn, M. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01458-0 · Cited by 60 · see citing works
“Indeed, AP-naïve first-episode patients (i.e. no prior exposure to APs) are more likely to develop AIWG, compared to patients of chronic AP use [25, 26, 63 • , 64].”
Result
Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists
Pisano, S., Catone, G., Veltri, S., Lanzara, V., Pozzi, M., Clementi, E., Iuliano, R., Riccio, M. P., Radice, S., Molteni, M., et al. (2016) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-016-0259-2 · Cited by 60 · see citing works
Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders – Baseline and two-years findings from the CHANGE trial
Jakobsen, A. S., Speyer, H., Nørgaard, H. C. B., Hjorthøj, C. R., Krogh, J., Mors, O. N., & Nordentoft, M. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.047 · Cited by 58 · see citing works
Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first‐episode psychosis patients: A 7‐month follow‐up study
Balõtšev, R., Haring, L., Koido, K., Leping, V., Kriisa, K., Zilmer, M., Vasar, V., Piir, A., Lang, A., & Vasar, E. (2017) · Early Intervention in Psychiatry · doi:10.1111/eip.12457 · Cited by 57 · see citing works
Brexpiprazole: A Review in Schizophrenia
Frampton, J. E. (2019) · Drugs · doi:10.1007/s40265-019-1052-5 · Cited by 57 · see citing works
The prevalence, risk factors and clinical correlates of obesity in Chinese patients with schizophrenia
Li, Q., Du, X., Zhang, Y., Yin, G., Zhang, G., Walss‐Bass, C., Quevedo, J., Soares, J. C., Xia, H., Li, X., et al. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.12.041 · Cited by 52 · see citing works
A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers
Silverman, B. L., Martin, W. F., Memişoğlu, A., DiPetrillo, L., Correll, C. U., & Kane, J. M. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.10.014 · Cited by 52 · see citing works
Effects of high intensity interval training among overweight individuals with psychotic disorders: A randomized controlled trial
Romain, A. J., Fankam, C., Karelis, A. D., Letendre, E., Mikolajczak, G., Stip, É., & Abdel‐Baki, A. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.12.021 · Cited by 52 · see citing works
Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis
Ellul, P., Delorme, R., & Cortese, S. (2018) · CNS Drugs · doi:10.1007/s40263-018-0571-z · Cited by 51 · see citing works
A systematic review of sex-based differences in effectiveness and adverse effects of clozapine
Alberich, S., Fernández-Sevillano, J., González–Ortega, I., Usall, J., Sáenz-Herrero, M., González–Fraile, E., & González-Pinto, A. M. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112506 · Cited by 51 · see citing works
“Although there are other antipsychotics such as amisulpride, aripiprazole and ziprasidone that cause a more moderate weight gain (Bai et al., 2017; Bak et al., 2014; Tek et al., 2016), these have been shown to be less effective in clinical terms than clozapine (Ifteni et al.”
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
Forbes, A., Hobart, M., Ouyang, J., Shi, L., Pfister, S., & Hakala, M. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy002 · Cited by 52 · see citing works
Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis
Bak, M., Drukker, M., Cortenraad, S. A. M., Vandenberk, E., & Gülöksüz, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244944 · Cited by 50 · see citing works
Self-citation
Development and external validation of the Psychosis Metabolic Risk Calculator (PsyMetRiC): a cardiometabolic risk prediction algorithm for young people with psychosis
Perry, B. I., Osimo, E. F., Upthegrove, R., Mallikarjun, P. K., Yorke, J., Štochl, J., Pérez, J., Zammit, S., Howes, O. D., Jones, P. B., et al. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00114-0 · Cited by 48 · see citing works
Pharmacological interventions for prevention of weight gain in people with schizophrenia
Agarwal, S. M., Stogios, N., Ahsan, Z. A., Lockwood, J., Duncan, M. J., Takeuchi, H., Cohn, T. A., Taylor, V. H., Remington, G. J., Faulkner, G., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013337.pub2 · Cited by 48 · see citing works
Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD)
Iffland, M., Livingstone, N., Jorgensen, M. L., Hazell, P., & Gillies, D. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011769.pub2 · Cited by 55 · see citing works
Physical health and mental illness: listening to the voice of carers
Happell, B., Wilson, K., Platania‐Phung, C., & Stanton, R. (2016) · Journal of Mental Health · doi:10.3109/09638237.2016.1167854 · Cited by 48 · see citing works
Drug‐Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism
Anyanwagu, U., IDRIS, I. R., & Donnelly, R. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.274 · Cited by 47 · see citing works
Sex Differences in Body Mass Index and Obesity in Chinese Patients With Chronic Schizophrenia
Li, Q., Chen, D., Liu, T., Walss‐Bass, C., Quevedo, J., Soares, J. C., Zhao, J., & Zhang, X. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000594 · Cited by 47 · see citing works
Free thyroxine and thyroid-stimulating hormone in severe mental disorders: A naturalistic study with focus on antipsychotic medication
Vedal, T. S. J., Steen, N. E., Birkeland, K. I., Dieset, I., Reponen, E. J., Laskemoen, J. F., Rødevand, L. N., Melle, I. S., Andreassen, O. A., Molden, E., et al. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.09.014 · Cited by 47 · see citing works
Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics
Álvarez-Herrera, S., Escamilla-Orozco, R. I., Contreras, O. M., Saracco, R., Flores-Medina, Y., Hurtado‐Alvarado, G., Maldonado-García, J. L., Becerril‐Villanueva, E., Pérez‐Sánchez, G., & Pavón, L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00195 · Cited by 47 · see citing works
Relative Risk of Acute Myocardial Infarction in People with Schizophrenia and Bipolar Disorder: A Population-Based Cohort Study
Wu, S., Chen, S., Liu, S., Sun, F., Juang, J. J., Lee, H., Kao, K., Dewey, M. E., Prince, M. J., & Stewart, R. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134763 · Cited by 45 · see citing works
Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis
Speyer, H., Westergaard, C., Albert, N., Karlsen, M., Stürup, A. E., Nordentoft, M., & Krogh, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.577919 · Cited by 44 · see citing works
Patients with psychiatric comorbidity can safely undergo bariatric surgery with equivalent success
Fuchs, H. F., Laughter, V., Harnsberger, C. R., Broderick, R. C., Berducci, M. A., DuCoin, C. G., Langert, J., Sandler, B. J., Jacobsen, G. R., Perry, W., et al. (2015) · Surgical Endoscopy · doi:10.1007/s00464-015-4196-8 · Cited by 44 · see citing works
Metabolic syndrome among older adults with schizophrenia spectrum disorder: Prevalence and associated factors in a multicenter study
Kassm, S. A., Hoertel, N., Naja, W., McMahon, K., Barrière, S., Blumenstock, Y., Portefaix, C., Raucher‐Chéné, D., Bera‐Potelle, C., Cuervo-Lombard, C.-V., et al. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.03.036 · Cited by 44 · see citing works
Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines
Connor, C. J. (2017) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s111041 · Cited by 46 · see citing works
“In addition, it is important to recognize that almost all antipsychotic agents can cause weight gain and/or metabolic syndrome, with olanzapine and clozapine posing the greatest risk, and amisulpride and aripiprazole with little to none.(110) As an interesting side note, studies have determined that this weight gain i…”
Greater body mass index is associated with reduced frontal cortical volumes among adolescents with bipolar disorder
Islam, A. H., Metcalfe, A. W. S., MacIntosh, B. J., Korczak, D. J., & Goldstein, B. I. (2018) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.170041 · Cited by 44 · see citing works
Obesity in Chinese patients with chronic schizophrenia: Prevalence, clinical correlates and relationship with cognitive deficits
Tian, Y., Liu, D., Wang, D., Wang, J., Xu, H., Dai, Q., Andriescue, E. C., Wu, H. E., Xiu, M., Chen, D., et al. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.10.017 · Cited by 43 · see citing works
Weight gain during incarceration: systematic review and meta‐analysis
Gebremariam, M. K., Nianogo, R. A., & Arah, O. A. (2017) · Obesity Reviews · doi:10.1111/obr.12622 · Cited by 41 · see citing works
The use of antipsychotic agents during pregnancy and the risk of gestational diabetes mellitus: a systematic review and meta-analysis
Wang, Z., Wong, I. C. K., Man, K. K. C., Alfageh, B. H., Mongkhon, P., & Brauer, R. (2020) · Psychological Medicine · doi:10.1017/s003329171900401x · Cited by 42 · see citing works
Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons
Kowalchuk, C., Kanagasundaram, P., Belsham, D. D., & Hahn, M. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.01.029 · Cited by 41 · see citing works
Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female Mice
Motyl, K. J., DeMambro, V., Barlow, D. J., Olshan, D. S., Nagano, K., Baron, R., Rosen, C. J., & Houseknecht, K. L. (2015) · Endocrinology · doi:10.1210/en.2015-1099 · Cited by 39 · see citing works
Genetic Correlation Profile of Schizophrenia Mirrors Epidemiological Results and Suggests Link Between Polygenic and Rare Variant (22q11.2) Cases of Schizophrenia
Duncan, L. E., Shen, H., Ballon, J. S., Hardy, K. V., Noordsy, D. L., & Levinson, D. F. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx174 · Cited by 38 · see citing works
Physical activity for patients with severe mental illness: Preferences, barriers and perceptions of counselling
Romain, A. J., Longpré-Poirier, C., Tannous, M., & Abdel‐Baki, A. (2020) · Science & Sports · doi:10.1016/j.scispo.2020.03.005 · Cited by 38 · see citing works
Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis
Suvitaival, T., Mantere, O., Kieseppä, T., Mattila, I. M., Pöhö, P., Hyötyläinen, T., Suvisaari, J., & Orešič, M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.222 · Cited by 38 · see citing works
Physical Health and Drug Safety in Individuals with Schizophrenia
Pringsheim, T. M., Kelly, M. A., Urness, D., Teehan, M. D., Ismail, Z., & Gardner, D. M. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717719898 · Cited by 38 · see citing works
Effects of psychopharmacological treatment with antipsychotic drugs on the vascular system
Kahl, K. G., Westhoff‐Bleck, M., & Krüger, T. H. C. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.09.001 · Cited by 38 · see citing works
Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?
Endomba, F. T., Tankeu, A. T., Nkeck, J. R., & Tochie, J. N. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01203-z · Cited by 38 · see citing works
Discovery of FDA-Approved Drugs as Inhibitors of Fatty Acid Binding Protein 4 Using Molecular Docking Screening
Wang, Y., Law, W.-K., Hu, J., Lin, H., Ip, T.-M., & Wan, D. C. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500503b · Cited by 39 · see citing works

S2. ANTIPSYCHOTICS RESULT IN WEIGHT GAIN BUT THE SEVERITY OF WEIGHT GAIN DIFFERS BETWEEN ANTIPSYCHOTICS
Bak, M., Drukker, M., Campforts, B. C. M., Cortenraad, S. A. M., Vandenberk, E., & Viechtbauer, W. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa031.068 · Cited by 1 · see citing works
Self-citation
Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis
Bak, M., Drukker, M., Cortenraad, S. A. M., Vandenberk, E., & Gülöksüz, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244944 · Cited by 50 · see citing works
Self-citation
Weight gain in antipsychotic-naive patients: a review and meta-analysis
Tarricone, I., Gozzi, B. F., Serretti, A., Grieco, D., & Berardi, D. (2009) · Psychological Medicine · doi:10.1017/s0033291709990407 · Cited by 112 · see citing works
Association between antipsychotic medication and clinically relevant weight change: meta-analysis
Campforts, B. C. M., Drukker, M., Crins, J., van Amelsvoort, T., & Bak, M. (2023) · BJPsych Open · doi:10.1192/bjo.2022.619 · Cited by 32 · see citing works
Self-citation
Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications
Tek, C., Küçükgöncü, S., Gülöksüz, S., Woods, S. W., Srihari, V. H., & Annamalai, A. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.140308 · Cited by 13 · see citing works

Authors: Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M.
Affiliations: Maastricht University Medical Centre (NL)
Máxima Medisch Centrum (NL)
Corresponding author: Bak, Maarten
ORCID: Bak, Maarten
Fransen, Annemarie
Drukker, Marjan
Venue: PLoS ONE
Publisher: Public Library of Science (PLoS)
Published: 2014-04-24
Volume: 9
Issue: 4
Pages: e94112
ISSN: 1932-6203 (ISSN-L)
DOI: 10.1371/journal.pone.0094112
PMC: PMC3998960
OpenAlex: W2089001223
Cited by: 490
References: 362
Citations by year: 2026: 17 · 2025: 31 · 2024: 39 · 2023: 42 · 2022: 47 · 2021: 48 · 2020: 45 · 2019: 55 · 2018: 50 · 2017: 43 · 2016: 39 · 2015: 28 · 2014: 5
FWCI: 5.28
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: PLoS ONE (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, other-oa)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Research Publications (Maastricht University) (publishedVersion, cc-by)
RePEc: Research Papers in Economics (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Figshare (submittedVersion, cc-by)
NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
Research Publications (Maastricht University) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
Keywords: antipsychotic drugs, weight gain, body mass index, antipsychotic switching, amisulpride, aripiprazole, ziprasidone, antipsychotic-naive patients, weight loss
MeSH terms: Bipolar Disorder, Humans, Schizophrenia, Antipsychotic Agents, Weight Gain, Body Mass Index, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks